Indecainide
Chemical compound
- none
- 9-[3-(isopropylamino)propyl]-9H-fluorene-9-carboxamide
- 74517-78-5
Y
73681-12-6 (HCl)
- 52194
- DB00192
Y
- 47194
Y
- 3AZF20DM1T
- D04521
Y
- ChEMBL1201242
N
- DTXSID2057819
- Interactive image
- O=C(N)C3(c1ccccc1c2c3cccc2)CCCNC(C)C
InChI
- InChI=1S/C20H24N2O/c1-14(2)22-13-7-12-20(19(21)23)17-10-5-3-8-15(17)16-9-4-6-11-18(16)20/h3-6,8-11,14,22H,7,12-13H2,1-2H3,(H2,21,23)
Y
- Key:UCEWGESNIULAGX-UHFFFAOYSA-N
Y
![☒](http://upload.wikimedia.org/wikipedia/commons/thumb/a/a2/X_mark.svg/7px-X_mark.svg.png)
![check](http://upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/7px-Yes_check.svg.png)
Indecainide (INN, trade name Decabid) is a class Ic antiarrhythmic agent.[1] Developed and marketed by Lilly, it has now been discontinued.
References
- ^ Jaillon P, Drici M (December 1989). "Recent antiarrhythmic drugs". The American Journal of Cardiology. 64 (20): 65J–69J. doi:10.1016/0002-9149(89)91203-4. PMID 2688391.
External links
- FDA drug details [1]
- v
- t
- e
Antiarrhythmic agents (C01B)
class I (Na+ channel blockers) |
| ||||||
---|---|---|---|---|---|---|---|
class III (Phase 3→, K+ channel blockers) | |||||||
class IV (Phase 4→, Ca2+ channel blockers) |
and antagonists
class II (Phase 4→, β blockers) |
|
---|---|
A1 agonist | |
M2 | |
α receptors |
Na+/ K+-ATPase |
---|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
![]() | This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e